National Bank of Canada
CRSP icon

National Bank of Canada’s CRISPR Therapeutics CRSP Stock Holding History

National Bank of Canada’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.7K Sell
1,361
-52,164
-97% -$2.75M ﹤0.01% 1894
2025
Q4 		$2.81M Buy
53,525
+43,704
+445% +$2.62M ﹤0.01% 1002
2025
Q3 		$636K Sell
9,821
-725,779
-99% -$41.7M ﹤0.01% 1304
2025
Q2 		$35.8M Buy
+735,600
New +$28.5M 0.03% 375
2024
Q3 		– Sell
-848
Closed -$45.6K – 2815
2024
Q2 		$45.6K Buy
848
+220
+35% +$12.7K ﹤0.01% 1713
2024
Q1 		$32.1K Sell
628
-40
-6% -$2.86K ﹤0.01% 1899
2023
Q4 		$44.1K Sell
668
-1,170
-64% -$64.7K ﹤0.01% 1808
2023
Q3 		$77.7K Buy
1,838
+445
+32% +$23K ﹤0.01% 1678
2023
Q2 		$78.2K Sell
1,393
-80
-5% -$4.54K ﹤0.01% 1655
2023
Q1 		$66.6K Sell
1,473
-6
-0.4% -$291 ﹤0.01% 1625
2022
Q4 		$60.1K Sell
1,479
-250
-14% -$13.3K ﹤0.01% 1685
2022
Q3 		$112K Buy
1,729
+536
+45% +$38.8K ﹤0.01% 1494
2022
Q2 		$73K Sell
1,193
-441
-27% -$25.9K ﹤0.01% 1645
2022
Q1 		$101K Buy
1,634
+476
+41% +$29.9K ﹤0.01% 1660
2021
Q4 		$88K Buy
+1,158
New +$101K ﹤0.01% 1665

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

National Bank of Canada's CRSP Position: Q1 2026 in Review

National Bank of Canada reduced its CRISPR Therapeutics (CRSP) stake by 97% in Q1 2026, selling an estimated $2.75M and leaving 1,361 shares worth $64.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

National Bank of Canada first reported a position in CRSP in Q4 2021 and has held it in 15 quarters since. The position peaked at $35.8M in Q2 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • National Bank of Canada held 1,361 shares of CRISPR Therapeutics worth $64.7K as of Q1 2026.
  • National Bank of Canada sold 52,164 CRISPR Therapeutics shares in Q1 2026, an estimated $2.75M.
  • CRISPR Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #1894 holding.
  • National Bank of Canada first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • National Bank of Canada's CRISPR Therapeutics position peaked at $35.8M in Q2 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.